Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 27, 2014

BioInvent Gives Immunotherapy Candidate Back to Alligator Bioscience

  • BioInvent International just sold back all its rights to preclinical cancer candidate ADC-1013 to Alligator Bioscience after having manufactured ADC-1013 successfully. The firm says it still plans to fulfill the remaining chemistry, manufacturing, and control activities necessary to supply the drug to its first-in-human study, which both companies expect to start by the end of 2014.

    ADC-1013, according to Alligator, is an antibody-based immunotherapy that can induce antitumor immune effects by activating CD40 receptors on antigen-presenting dendritic cells. BioInvent describes the candidate as a FIND®-optimized n-CoDeR® antibody, FIND being Alligator's in vitro based antibody optimization technology and n-CoDeR being BioInvent's antibody library containing 20 billion human antibody genes. 

    Alligator’s CEO Sibylle Lenz said in a statement that the firm is pleased to be regaining full control over ADC-1013. "Cancer immunotherapy is a very exciting area and we have a strong support from our main investors to move ahead with the clinical trial as scheduled," she added.

    With its work with ADC-1013 being wrapped up, BioInvent says it plans to focus on its fully owned drug development candidates BI-505 (currently in Phase II for multiple myeloma) and BI-1206, which has a first-in-human study in non-Hodgkin’s lymphoma coming up in late 2014/early 2015.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »